Summit BHC jobs

Licensed Practical Nurse- Full Time Raleigh Oaks Behavioral Health posted: Posted 21 Days Ago

Chief Nursing Officer- Behavioral Health Miramont Behavioral Health posted: Posted 30+ Days Ago

Director of Nursing | Recovery Ivory Plains Recovery Center posted: Posted Today

RN Supervisor- Nights Las Cruces Recovery Center posted: Posted Yesterday

LVN - Days (Full-Time) Stone River Recovery Center posted: Posted 30+ Days Ago

Phlebotomist - PRN Behavioral Healthcare Facility Las Cruces Recovery Center posted: Posted 22 Days Ago

PT Behavorial Health Technician-Acute -Weekends Highland Hospital posted: Posted 30+ Days Ago

Lead, Regional Medical Science Director Raleigh, North Carolina, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

Therapist FT Sun - Thurs (10am - 7pm) Iron Bridge Recovery Center posted: Posted 17 Days Ago

RN Manager Raleigh Oaks Behavioral Health posted: Posted 30+ Days Ago

Maintenance Technician- Acute The Pavilion at Williamsburg Place posted: Posted 30+ Days Ago

LVN - Nights Stone River Recovery Center posted: Posted 30+ Days Ago

RN-Nights-Acute Highland Hospital posted: Posted 30+ Days Ago

Counselor - (Master's Level, LPC, LCSW, CAADC, CADC) Mountain Laurel Recovery Center posted: Posted 25 Days Ago

Counselor LPC, LCSW or LMFT The Ranch at Dove Tree posted: Posted 9 Days Ago

Executive Director, US Market Access Strategy Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

Activity Assistant - Acute PRN Palms Behavioral Health posted: Posted 14 Days Ago

PRN Recovery Coach - Weekends The Aviary Recovery Center posted: Posted 3 Days Ago

Weekend Security Guard Wooded Glen Recovery Center posted: Posted 2 Days Ago

Director of Plant Ops - Healthcare Miramont Behavioral Health posted: Posted 30+ Days Ago

LPN FT Days Las Cruces Recovery Center posted: Posted 30+ Days Ago

Senior Director of Technical QA (GMP) Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

PRN Recreational Therapist Carolina Dunes Behavioral Health posted: Posted 30+ Days Ago

RN, night shift PRN, weekends Fri/Sat shifts, minimum 3 shifts a month. Twin Lakes Recovery Center posted: Posted 2 Days Ago